Immune action at a distance
MIT and MGH researchers design a local, gel-based drug-delivery platform that may provoke a system-wide immune response to metastatic tumors.
MIT and MGH researchers design a local, gel-based drug-delivery platform that may provoke a system-wide immune response to metastatic tumors.
Using fluorescent labels that switch on and off, MIT engineers can study how molecules in a cell interact to control the cell’s behavior.
First-year MIT student and former Time “Kid of the Year” honored for promoting science and innovation among youth and inspiring them with several inventions.
The new sensor measures heart and breathing rate from patients with sleep apnea and could also be used to monitor people at risk of opioid overdose.
MIT researchers will partner on interdisciplinary research in human biology and disease.
MIT spinout Kronos Bio, founded by Associate Professor Angela Koehler, studies the complex signaling networks of cancer cells to find new drug targets.
The device contains encapsulated cells that produce insulin, plus a tiny oxygen-producing factory that keeps the cells healthy.
The findings could help doctors identify cancer patients who would benefit the most from drugs called checkpoint blockade inhibitors.
Coupling engineered bacteria with low-power electronics could be highly effective in diagnosis, treatment of bowel diseases.
The new approach could lead to intranasal vaccines for Covid-19 and other respiratory diseases.
Nine faculty members have been granted tenure in six units across MIT’s School of Engineering.
The Koch Institute’s Annual Symposium highlights emerging successes and challenges in the advancement of vaccines to prevent and treat cancer.
Faculty members were recently granted tenure in the departments of Biology, Brain and Cognitive Sciences, Chemistry, EAPS, and Physics.
In addition to turning on genes involved in cell defense, the STING protein also acts as an ion channel, allowing it to control a wide variety of immune responses.
MIT researchers find timing and dosage of DNA-damaging drugs are key to whether a cancer cell dies or enters senescence.